Estrogens, anti-estrogens and familial breast cancer;Les formes héréditaires de cancer du sein liées à BRCA1 et BRCA2 sont-elles sensibles aux œstrogènes?

Bulletin du Cancer

Volumn 91, Issue 7-8, 2004, Pages 583-591

  Pujol, Pascal ^a   This, Pascale ^b   Noruzinia, Mehrdad ^a   Stoppa Lyonnet, Dominique ^b   Maudelonde, Thierry ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b INSTITUT CURIE   (France)

Author keywords

BRCA1; Estrogen; Familial breast cancer; Tamoxifen

Indexed keywords

ANTIESTROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; FAMILIAL CANCER; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HORMONE SENSITIVITY; HUMAN; OVARIECTOMY; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PHENOTYPE; TAMOXIFEN;

EID: 4344648157     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history : a combined analysis of 22 studies. Am J Hum Genet 2003 ; 72 : 1117-30.
2. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998 ; 62 : 676-89.
3. Eisinger F, Alby N, Bremond A, Dauplat J, Espie M, Janiaud P, et al. Inserm ad hoc committee : Recommendations for the management of women with a genetic risk for developing cancer of the breast and/or the ovary. Bull Cancer 1999 ; 86 : 307-13.
4. Pujol P, Maudelonde T. Physiologie et physio-pathologie de la glande mammaire. Encycl Med Chir Endocrinologie-Nutrition Elsevier, Paris, 1997 10-034-E-10, 10 p.
5. Beral V, Banks E, Reeves G, Bull D. Breast cancer and hormone-replacement therapy : the Million Women Study. Lancet 2003 ; 362 : 1330-1.
6. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy : scientific review. JAMA 2002 ; 288 : 872-81.
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women : principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002 ; 288 : 321-33.
8. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. J Natl Cancer Inst 1998 ; 90 : 1371-88.
9. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nature Genet 2002 ; 31 : 33-6.
10. Bonadona V, Lasset C. Inherited predisposition to breast cancer : after the BRCA1 and BRCA2 genes, what next ? Bull Cancer 2003 ; 90 : 587-94.
11. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002 ; 108 : 171-82.
12. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 2000 ; 21 : 147-51.
13. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998 ; 90 : 1138-45.
14. Eisinger F, Nogues C, Guinebretiere JM, Peyrat JP, Bardou VJ, Noguchi T, et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer 1999 ; 84 : 263-7.
15. Eisinger F, Nogues C, Birnbaum D, Jacquemier J Sobol H. BRCA1 and medullary breast cancer. JAMA 1998 ; 280 : 1227-8.
16. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, et al. Familial invasive breast cancers : worse outcome related to BRCA1 mutations. J Clin Oncol 2000 ; 18 : 4053-9.
17. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 : National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001 ; 286 : 2251-6.
18. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 1994 ; 74 : 1601-6.
19. Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 2001 ; 7 : 1937-45.
20. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen ? Endocr Rev 2000 ; 21 : 40-54.
21. Hilakivi-Clarke L. Estrogens, BRCA1, and breast cancer. Cancer Res 2000 ; 60 : 4993-5001.
22. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genet 1995 ; 11 : 17-26.
23. Gudas JM, Nguyen H, Li T, Cowan KH. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995 ; 55 : 4561-5.
24. Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, et al. BRCA1 expression is not directly responsive to estrogen. Oncogene 1997 ; 14 : 115-21.
25. Bennett LM, McAllister KA, Malphurs J, Ward T, Collins NK, Seely JC, et al. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res 2000 ; 60 : 3461-9.
26. Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 1999 ; 84 : 258-62.
27. Catteau A, Morris JR. BRCA1 methylation : a significant role in tumour development ? Semin Cancer Biol 2002 ; 12 : 359-71.
28. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999 ; 284 : 1354-6.
29. Hamilton SA, Mack TM. Puberty and Genetic Susceptibility to Breast Cancer in a case-control study in twins. N Engl J Med 2003 ; 348 : 2313-22.
30. Monteiro AN. BRCA1 : the enigma of tissue-specific tumor development. Trends Genet 2003 ; 19 : 312-5.
31. Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P, Grenier J. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998 ; 83 : 698-705.
32. Pujol P, Galtier-Dereure F, Bringer J. Obesity and breast cancer risk. Hum Reprod 1997 ; 12 (Suppl. 1) : 116-25.
33. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophotectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002 ; 346 : 1609-15.
34. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999 ; 91 : 1475-9.
35. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. The Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002 ; 346 : 1616-22.
36. Ursin G, Henderson BE, Haile RW, Pike MC, Zhon N, Diep A, Bernstein L. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women ? Cancer Res 1997 ; 57 : 3678-81.
37. Grabrick DM, Hattmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast - cancer. JAMA 2000 ; 284 : 1791-8.
38. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002 ; 94 : 1773-9.
39. Whittemore AS, Harris R, Itnyre J. Collaborative Ovarian Group. Characteristics relating to ovarian cancer risk : collaborative analysis of 12 US case-control studies. II. invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992 ; 136 : 1184-203.
40. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998 ; 339 : 424-8.
41. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and non carriers of a BRCA 1 or 2 mutations. N Engl J Med 2001 ; 345 : 235-40.
42. Familial breast cancer : collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 without the disease. Lancet 2001 ; 358 : 1389-99.
43. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999 ; 354 : 1846-50.
44. Johannsson O, Loman N, Borg A, Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 1998 ; 352 : 1359-60.
45. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001 ; 61 : 5420-4.
46. Grabrick DM, Anderson VE, King RA, Kushi LH, Sellers TA. Inclusion of risk factor covariates in a segregation analysis of a population-based sample of 426 breast cancer families. Genet Epidemiol 1999 ; 16 : 150-64.
47. Bruner JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, et al. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 1998 ; 90 : 761-6.
48. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990 ; 162 : 502-14.
49. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999 ; 91 : 1829-46.
50. Powles T. Tamoxifen and familial breast cancer : tumor prevention and genetics. Eur J Cancer 2002, Suppl. (S15).
51. e conférence de Saint-Gall. Lettre du cancérologue 2002 ; 11 : 149-51.
52. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers : a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000 ; 356 : 1876-81.
53. Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer 2002 ; 86 : 218-21.
54. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000 ; 283 : 617-24.
55. Eisinger F, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Julian-Reynier C, Sobol H. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation : computed efficacy, effectiveness and impact. Int J Oncol 2001 ; 18 : 5-10.
56. Foulkes WD, Goffin J, Brunet JS, Begin LR, Wong N, Chappuis PO. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst 2002 ; 94 : 1504-6.
57. Lasset C, Bonadona V. Medical management of women with inherited predisposition to breast cancer : indications and procedures for mammographic screening. Bull Cancer 2001 ; 88 : 677-86.
58. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Betesford SA, Pettinger M, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures : the Women's Health Initiative randomized trial. JAMA 2003 ; 290 : 1739-48.
59. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd et al. American Society of Clinical Oncology Technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifen, and aromatase inhibition. J Clin Oncol 2002 ; 20 : 3328-43.
60. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effects of raloxifen on risk of breast cancer in postmenopausal women. Results from the More randomized trial. JAMA 1999 ; 281 : 2189-97.